OC
ATXS

Oppenheimer & Co’s Astria Therapeutics ATXS Stock Holding History

Oppenheimer & Co’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,944
Closed -$182K – 1438
2024
Q1 		$182K Sell
12,944
-1,500
-10% -$18.7K ﹤0.01% 1355
2023
Q4 		$111K Sell
14,444
-83
-0.6% -$459 ﹤0.01% 1330
2023
Q3 		$108K Hold
14,527
– – ﹤0.01% 1316
2023
Q2 		$121K Sell
14,527
-1,500
-9% -$17.3K ﹤0.01% 1339
2023
Q1 		$213K Buy
16,027
+11
+0.1% +$149 ﹤0.01% 1242
2022
Q4 		$238K Sell
16,016
-1,800
-10% -$18.6K 0.01% 1176
2022
Q3 		$161K Sell
17,816
-5,800
-25% -$38.9K ﹤0.01% 1252
2022
Q2 		$71K Hold
23,616
– – ﹤0.01% 1354
2022
Q1 		$158K Buy
23,616
+1,800
+8% +$10.7K ﹤0.01% 1386
2021
Q4 		$118K Buy
21,816
+9,567
+78% +$62.9K ﹤0.01% 1436
2021
Q3 		$108K Buy
12,249
+1,999
+20% +$19.2K ﹤0.01% 1446
2021
Q2 		$130K Sell
10,250
-917
-8% -$11.9K ﹤0.01% 1457
2021
Q1 		$194K Sell
11,167
-533
-5% -$9.63K ﹤0.01% 1354
2020
Q4 		$150K Sell
11,700
-5,920
-34% -$106K ﹤0.01% 1281
2020
Q3 		$654K Sell
17,620
-290
-2% -$11.5K 0.02% 723
2020
Q2 		$691K Sell
17,910
-120
-0.7% -$4.27K 0.02% 690
2020
Q1 		$449K Buy
18,030
+4,988
+38% +$155K 0.01% 771
2019
Q4 		$462K Sell
13,042
-266
-2% -$8.38K 0.01% 864
2019
Q3 		$431K Buy
13,308
+1,857
+16% +$73.4K 0.01% 844
2019
Q2 		$554K Sell
11,451
-3,863
-25% -$175K 0.02% 768
2019
Q1 		$727K Buy
15,314
+7,550
+97% +$256K 0.02% 683
2018
Q4 		$203K Sell
7,764
-710
-8% -$26.9K 0.01% 1097
2018
Q3 		$407K Buy
8,474
+5,174
+157% +$232K 0.01% 942
2018
Q2 		$190K Buy
3,300
+400
+14% +$36.9K 0.01% 1229
2018
Q1 		$315K Hold
2,900
– – 0.01% 1034
2017
Q4 		$259K Buy
2,900
+83
+3% +$9.77K 0.01% 1117
2017
Q3 		$358K Buy
2,817
+817
+41% +$68.1K 0.01% 966
2017
Q2 		$169K Buy
2,000
+500
+33% +$41.6K ﹤0.01% 1212
2017
Q1 		$144K Buy
+1,500
New +$207K ﹤0.01% 1221

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Oppenheimer & Co's ATXS Position: Q2 2024 in Review

Oppenheimer & Co sold out of Astria Therapeutics (ATXS) in Q2 2024, closing a stake of 12,944 shares — an estimated $182K sold.

Oppenheimer & Co first reported a position in ATXS in Q1 2017 and held it in 29 quarters. The position peaked at $727K in Q1 2019. 100 funds tracked by Wall St. Rank hold ATXS as of Q2 2024.

  • Oppenheimer & Co reported no remaining Astria Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Oppenheimer & Co sold 12,944 Astria Therapeutics shares in Q2 2024, an estimated $182K.
  • Oppenheimer & Co first reported a position in Astria Therapeutics in Q1 2017 and held it in 29 quarters.
  • Oppenheimer & Co's Astria Therapeutics position peaked at $727K in Q1 2019.
  • 100 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2024.

Based on Oppenheimer & Co's 13F filing for Q2 2024, filed 8 Aug 2024.